Advertising & Exhibiting Opportunities
Thank you for your interest, please complete the advertising enquiry form so we may accommodate your request quickly.
MOST POPULAR THIS MONTH
Immunotherapy innovation: myNEO Therapeutics’ Cedric Bogaert
During the Congress in Barcelona last month we were delighted to speak to so many of our fantastic speakers and exhibitors as part of our Congress Conversations series. One of these speakers was myNEO Therapeutics' Cedric Bogaert, who joined us for the cancer keynote...
Merck (MSD) shares STRIDE-3 pneumococcal vaccine insights
In November 2023 Merck, which is known as MSD outside the US and Canada, announced results from a Phase III trial evaluating the company’s investigational 21-valent pneumococcal conjugate vaccine for protection of adults. The release was followed up by details shared...
CEPI, IVI and Gambia’s MRC launch Preparedness Programme
In November 2023 CEPI, IVI, and Gambia’s Medical Research Council Unit The Gambia (MRCG) announced the launch of the Research Preparedness Programme West Africa (RPPWA). IVI will co-lead the RPPWA as “Technical Coordinating Partner”. It will support a “consortium of...
Canada’s VIDO awarded IDIQ contract by US NIAID
In November 2023 the University of Saskatchewan’s Vaccine and Infectious Disease Organisation (VIDO) announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the US NIAID. One of seven organisations selected to be a member in...
Back to VacTrack: digital solutions with Gabriella and Emily
With the World Vaccine Congress West Coast kicking off we are pleased to share another exclusive interview. This time we are glad that start-up VacTrack were happy to catch up with us again after our interview in Washington earlier this year. We spoke to Gabriella...
UKHSA confirms human case of influenza A(H1N2)v
In November 2023 the UKHSA stated that a single human case of influenza A(H1N2)v has been detected in the UK through routine surveillance. Reporting that it is “working closely with partners” to characterise the pathogen and assess the risk to human health, UKHSA...
Re-engineered clamp platform produces safe vaccine
The University of Queensland (UQ) announced in November 2023 that its “re-engineered clamp platform” has produced a vaccine that is “equally safe and virus-neutralising" as an approved vaccine “considered among the best in its class”. This technology was identified...
Security and self-reliance: Africa CDC’s Akhona Tshangela
Our next interview in the European Congress series is with Africa CDC's Akhona Tshangela, who joined us at the event for sessions on vaccine manufacturing capacity from a global and an African perspective. We were thrilled that she had time to speak to us about her...
